NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Announces Launch of ‘OptHemp’ Premium Hemp Health Product Line

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX), through wholly-owned subsidiary Chinesehempoil.com Inc., this morning announced plans to launch its own premium hemp health product line, ‘OptHemp’, as well as its first private label product, OptHemp Ultra Premium Hemp Oil. “We believe that the desire for better quality of life in the Chinese community, coupled with … Continue reading “NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Announces Launch of ‘OptHemp’ Premium Hemp Health Product Line”

ChineseInvestors.com (CIIX) Growing Rapidly in a Rapidly Growing Market

Savvy investors study multiple factors to identify potential stock winners. Stock screeners scan thousands of companies for insights and data to discern uncommon opportunities. The criteria utilized in a stock screening system is obviously influenced by an individual’s investment proclivities such as high yield, value, growth or price momentum, however, most stock screening systems are … Continue reading “ChineseInvestors.com (CIIX) Growing Rapidly in a Rapidly Growing Market”

NetworkNewsBreaks – Consilium Global Research Report Projects ChineseInvestors.com, Inc. (CIIX) Will Reach $14.8M in Revenues by FY2020

A recent research report published by Consilium Global Research predicts that ChineseInvestors.com (OTCQB: CIIX) will reach revenues of $14.8 million by fiscal year 2020 and that the company will undergo a major transformation this year as it pursues a bigger stake in the cannabis market. As cited in the report, ChineseInvestors.com achieved $930,000 in revenue … Continue reading “NetworkNewsBreaks – Consilium Global Research Report Projects ChineseInvestors.com, Inc. (CIIX) Will Reach $14.8M in Revenues by FY2020”

ChineseInvestors.com, Inc. (CIIX) Projected To Reach Revenue of $14.8 Million by FY2020 in Consilium Global Research Report

ChineseInvestors.com, Inc. (OTCQB: CIIX) is projected to reach revenues of $14.8 million by fiscal year 2020, according to a new research report by Consilium Global Research (http://nnw.fm/kKO7e). Per the report, the company did $930,000 in revenue for fiscal 2016 and is projected to grow at a compound annual growth rate (CAGR) of approximately 100% through … Continue reading “ChineseInvestors.com, Inc. (CIIX) Projected To Reach Revenue of $14.8 Million by FY2020 in Consilium Global Research Report”

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Pursues Continued Success in CBD Markets

Leveraging its achievements of amassing a 100,000+ user base, establishing a recognizable 18-year-old brand, and sharpening its focus on a market that exceeds two billion Chinese-speaking individuals, ChineseInvestors.com (OTCQB: CIIX) has reached a first-in-the-marketplace milestone by launching the world’s first and only Chinese language, cannabinoid-based therapeutic health products web store, http://www.ChineseCBDoil.com. After making a successful … Continue reading “NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Pursues Continued Success in CBD Markets”

ChineseInvestors.com, Inc. (CIIX) Aims to Excel in CBD Markets

For nearly two decades, ChineseInvestors.com (OTCQB: CIIX) has delivered a wide range of products, information, and services, including several subscription-based services, for the global Chinese speaking population. The specialized investment services company provides real-time market commentary, analysis, and education-related information in the Chinese language, as well as offering consultation, advertising, and public relations services. The … Continue reading “ChineseInvestors.com, Inc. (CIIX) Aims to Excel in CBD Markets”

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Adds Summer Yun as CEO of CBD Biotechnology Co., Ltd.

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its appointment of Summer (XiangYang) Yun as chief executive officer of its CBD Biotechnology Co., Ltd. subsidiary, which it originally launched in March of this year. Yun brings over 25 years of marketing and branding experience to the CIIX team. As CEO of CBD Biotechnology, … Continue reading “NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Adds Summer Yun as CEO of CBD Biotechnology Co., Ltd.”

ChineseInvestors.com, Inc. (CIIX) Set to Capitalize on Meteoric Growth of CBD Market

The chemical in marijuana that causes euphoria is delta-9 tetrahydrocannabinol, or THC. There are also over 100 other cannabinoid chemicals in the plant, including cannabidiol (CBD), one of the main active chemical compounds found in marijuana. CBD doesn’t make people high, isn’t intoxicating or addictive, and is gaining widespread acceptance as a natural and effective … Continue reading “ChineseInvestors.com, Inc. (CIIX) Set to Capitalize on Meteoric Growth of CBD Market”

ChineseInvestors.com, Inc. (CIIX) Raises Funds through a Private Placement, Sales of Equities, and Preferred Stock Offerings

ChineseInvestors.com, Inc. (OTCQB: CIIX) is raising funds in a series of offerings, equity sales and a private placement to meet its liquidity needs, even as it reported a 95% gain in its year-over-year operating revenues for the three months ended February 28, 2017. It has begun a private placement of a new series of its … Continue reading “ChineseInvestors.com, Inc. (CIIX) Raises Funds through a Private Placement, Sales of Equities, and Preferred Stock Offerings”

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Reports 95% YOY Revenue Growth for Quarter Ended February 28, 2017

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning offered investors an update on its financial and business achievements for the fiscal third quarter ended February 28, 2017, as well as its outlook for the remainder of the current fiscal year and 2018. Among the highlights, the company reported significantly higher revenues for both the … Continue reading “NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Reports 95% YOY Revenue Growth for Quarter Ended February 28, 2017”

Contact us: 212.418.1217